Articles tagged with Colitis
Researchers have identified three previously unknown genotypes of Helicobacter bacteria in pygmy sperm whales stranded along the southeastern US coast. The discovery raises new questions about microbial pathogens on ocean health and their impact on vulnerable species.
Researchers found that mice without the ANGPTL4 gene were protected from intestinal inflammation and colon tumors due to altered macrophage behavior. The study suggests that early-life inflammatory events can shape long-term immune programming, providing resistance to future challenges.
Insilico Medicine presents three abstracts at the 2026 Crohn's & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411. The first-in-human Phase 1 results show no serious adverse events or deaths reported, with a favorable pharmacokinetic profile supporting gut restriction.
A new international study found significant changes in gut bacteria at the onset of inflammatory bowel disease (IBD), a condition that affects the digestive system. The study reveals a loss of beneficial anaerobic bacteria and an increase in oxygen-tolerant bacteria, which may trigger inflammation.
The Algae for Health in Food and Pharma summit explores the latest developments in algae cultivation and processing, food innovation, and pharmaceutical applications. The event aims to advance the understanding of algae's health potential and highlight its applications across the food and pharmaceutical sectors.
Researchers discovered a new enzyme produced by Bacteroides fragilis that activates pain signaling. The enzyme is targeted with nanoparticles to develop treatments for gut pain in inflammatory bowel disease and irritable bowel syndrome. The studies aim to restore balance between good and bad bacteria to reduce symptoms.
The Crohn's & Colitis Foundation has launched GLIDE, an integrated global registry to connect patient data from IBD registries worldwide. This initiative aims to accelerate insights into complex clinical questions, driving improvements in care for those living with Crohn's disease and ulcerative colitis.
A new study published in Molecular Nutrition and Food Research found that red meat consumption causes an imbalance of bacteria in the intestinal microbiota, leading to exacerbated colonic inflammation. The diets resulted in a decrease in beneficial bacterial strains and an increase in pro-inflammatory cells.
Researchers at ETH Zurich and Stanford University quantified the number of molecules produced by gut bacteria that reach the human body daily. This knowledge helps understand how the gut microbiome influences health and behavior.
Researchers discovered pyruvate's ability to block TNFα/NF-κB signaling and directly target cytosolic phospholipase A2 (cPLA2), revealing a novel mechanism of action. This finding positions pyruvate as a unique, multifunctional therapeutic candidate for ulcerative colitis and potentially other inflammatory diseases.
A study by University of California, Riverside researchers found that inhaling agricultural dust can alter the gut microbiome and impair intestinal function, leading to increased 'leaky gut' and associated chronic diseases. The study highlights the need for protective measures for agricultural workers.
A large-scale study found no association between medication use and the development of microscopic colitis, contradicting previous findings. SSRIs were linked to a slightly higher risk, but also increased the likelihood of receiving a colonoscopy.
A study has discovered a connection between ferroptosis, a type of iron-dependent cell death, and inflammatory bowel disease. Lipid ROS activate ferroptosis, which drives cell death in the colon lining, and inhibiting this process may lead to new treatment options for IBD.
Researchers have discovered that supplementing with isobutyrate eases intestinal inflammation and restores gut balance in a pig model of colitis. The study shows that isobutyrate shifts the microbiome toward beneficial bacteria, reduces diarrhea and bleeding, and strengthens the intestinal barrier.
Damage to the intestinal barrier is a key factor in IBD pathogenesis. The barrier maintains homeostasis by preventing harmful substances from entering systemic circulation. Emerging therapeutic strategies target oxidative stress modulation, microbiota restoration, and autophagy regulation.
Microscopic colitis is a chronic inflammatory condition characterized by watery diarrhea and distinctive histologic features. The two primary subtypes are collagenous colitis and lymphocytic colitis, with collagenous colitis showing a stronger female predominance.
A pioneering research brings psychedelic medicine into gastroenterology, exploring psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). Dr. Erin E. Mauney's study modulates interoception and uses integrated therapy sessions with neuroimaging to track brain changes.
A global study describes four distinct stages of inflammatory bowel disease (IBD) as it spreads to newly developing regions in Africa, Asia, and Latin America. The research provides resources and guidance for local healthcare systems coping with the growing burden of IBD patients.
Researchers find inhibiting TMEM219 signaling restores mucosal healing in inflammatory bowel diseases and protects intestinal stem cells from death. The study suggests TMEM219 overactivation induces intestinal stem cell death, preventing mucosal renewal during inflammation.
Researchers from UCalgary and Chinese University of Hong Kong found that IBD progresses through four predictable epidemiological stages as it spreads globally. The study forecasts a major rise in IBD prevalence in Canada by 2045, with countries in North America, Europe, and Oceania reaching Stage 3 (compounding prevalence). Developing ...
Repeated esophagogastroduodenoscopy and colonoscopy enhance lesion detection, particularly in cases with active bleeding or poor visualization. The diagnostic accuracy of these procedures increases patient outcomes.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
Crohn's & Colitis Congress showcases cutting-edge research on IBD treatment barriers, genetic factors, and cardiovascular safety. Key studies reveal significant financial sacrifices made by patients to access care and identify epigenetic clues for Crohn's disease development.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers have reviewed the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells in treating inflammatory bowel disease. The study highlights the immunomodulatory, pro-regenerative, and anti-apoptotic properties of these vesicles, which may offer a safer alternative to conventional therapies.
The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis. The guideline groups available treatments into 'efficacy buckets' to facilitate personalized treatment planning, taking into account patient risk factors and disease severity.
A study published in Food Innovation and Advances found that M3G supplementation improved colonic mucosal barrier function, reducing inflammation and increasing physical barrier strength. The compound inhibited the over-activation of the Notch signaling pathway, suggesting its potential therapeutic application for intestinal health.
Researchers from USTC identified a causal link between microbial regulation and colitis exacerbation, proposing a treatment approach by blocking the enterococcus-tyramine-ADRA2A axis. This study provides new ways for treating inflammatory bowel disease.
A groundbreaking IBD study aims to identify biomarkers for personalized treatment, monitoring, and prediction. Researchers will collect genomic data from 1,000 newly diagnosed patients in the UK over four years.
The study reveals that 5S-Heudelotinone regulates the immune system by reducing pro-inflammatory immune cell numbers, maintaining intestinal mucosal integrity by modulating tight junctions. It also increases short-chain fatty acids and alters gut microbiota diversity, highlighting its potential as a novel treatment for IBD and CAC.
Research suggests that microbes in the human gut influence social behavior, with certain bacteria offering protection against intestinal problems. The study found specific species of Blautia and Bacteroides uniformis that may benefit people with autism and GI disorders.
Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.
A new study using spatial transcriptomics has generated a unique spatial atlas of intestinal cells in both healthy and inflamed states. The research reveals the evolution of cell populations during inflammation, particularly highlighting the significance of fibroblasts in response to gut inflammation.
Researchers at MBL have found a genetic arrangement that confers antibiotic resistance to the bacterium Bacteroides fragilis, which may help it protect itself from tetracycline. The study highlights the role of transposons in horizontal gene transfer and potential mechanisms for controlling gene expression.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
Researchers at University of Tsukuba discovered a correlation between hypoxia levels and clinical symptoms in UC patients. Lower oxygen saturation in the rectal mucosa was associated with greater severity of colitis, making this method a potential tool for objective measurement of disease activity.
Cancer immunotherapy can cause severe colitis due to hyper-activated immune T cells and deleted regulatory T cells. Researchers at Michigan Medicine have identified a new mouse model that develops colitis after treatment with antibodies used for tumor immunotherapy, revealing the mechanism behind this side effect.
A new study finds that 10% of patients with microscopic colitis are unaware of their diagnosis, while 15% of those without the condition were unsure or thought they had it. Despite this, many cases remain symptomatic and undertreated, emphasizing the importance of follow-up appointments and education.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
A study published in mSystems found that mice fed a broccoli sprout diet had milder disease symptoms and richer gut microbial communities compared to those not exposed. The researchers suggest that broccoli sprouts could be used as a treatment strategy for patients with IBD.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
Nearly 70% of adolescents and young adults with ulcerative colitis discontinue treatment within a year of diagnosis, putting them at risk of disease relapse. The study highlights the need for active follow-up by GPs to monitor medication adherence and affordability.
Researchers developed a platform that allows engineered biosensor bacteria to safely pass through the gastrointestinal tract in animal models. The platform enables real-time monitoring of gut health and can be used to diagnose and monitor various diseases, including inflammatory bowel disease. It has the potential to revolutionize pati...
Researchers found that a diet high in soybean oil decreases beneficial bacteria and increases harmful bacteria, leading to increased inflammation and susceptibility to colitis. Olive oil, with lower amounts of linoleic acid, is considered a healthier alternative.
A UNIGE team has developed small beads encapsulating fecal bacteria for treating a serious intestinal infection. The technology overcomes obstacles in current treatments, allowing for easier and more comfortable administration.
A new study by Oxford researchers has found vedolizumab to be effective in inducing remission in patients with chronic pouchitis after surgery for ulcerative colitis. The treatment improved remission rates and quality of life, making it a game-changer for these patients.
A study published in iScience reveals that fibroblasts cooperate with myeloid cells to produce IL-11, protecting the mucosal epithelium from damage during acute colitis. The interaction between fibroblasts and myeloid cells is crucial for maintaining intestinal homeostasis.
Researchers have isolated two new bacterial species from patients with inflammatory bowel disease (IBD), which break down the protective mucus layer of the gut. The bacteria, Allobaculum mucilyticum and Allobaculum fili, are highly efficient at degrading intestinal mucus, leading to potent immune responses.
Salk scientists have developed a new therapeutic compound called FexD, which reverses gut inflammation in mouse models of inflammatory bowel disease. By activating the master regulator protein FXR, FexD reduces inflammation and restores balance to the digestive system.
A new study reveals that pain neurons in mice regulate mucus production and stimulate intestinal cells to release more mucus during inflammation. This protective mechanism helps maintain gut homeostasis and prevent colitis.
Researchers found that certain types of dietary fiber cause inflammation in IBD patients, worsening symptoms. A stool test is being developed to predict individual responses to dietary fibers, enabling tailored recommendations.
A study published in Frontiers in Immunology found that Japanese herbal medicine DKT reduces colitis severity by preventing gut bacteria loss and increasing immune cells. It restores Lactobacillus levels and promotes type 3 innate lymphoid cells, alleviating inflammatory responses.
Researchers developed an AI system that classifies IBDN lesions accurately, displaying image-based diagnostic ability with 64.5% sensitivity and 89.5% specificity. The correct diagnosis rate of the AI system was 79.0, surpassing that of endoscopists, who achieved a 77.8% accuracy rate.
A new study found that exposure to dogs, particularly from ages 5 to 15, was linked to healthy gut permeability and balance in the gut microbiome. Additionally, growing up in a large family with three or more siblings may also provide protection against Crohn's disease by influencing microbiome composition.
A new study suggests that growing up with dogs and in large families may lower the risk of inflammatory bowel disease. Exposure to dogs, particularly between ages 5-15, was linked to healthy gut permeability and a balanced immune response, which may help protect against Crohn's disease.
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Scientists from Tokyo Medical and Dental University have developed a protocol to transplant 3D cellular structures called organoids into the colon to repair damaged intestinal tissue. This approach shows promise as a quick, reproducible, and minimally invasive method for treating ulcerative colitis.
Scientists have identified a key receptor in the digestive tract that triggers pain and inflammation in the colon. By blocking this receptor from entering cells, researchers found significant reduction in pain and inflammation. This discovery holds promise for treating inflammatory bowel disease.
A recent study by researchers at Case Western Reserve University found that Candida tropicalis fungus can trigger chronic inflammation in the gut microbiome of Crohn's disease patients. This imbalance of fungi and bacteria can create a predisposition to inflammatory bowel disease.
Researchers discovered that people with inflammatory bowel disease (IBD) have higher levels of microplastics in their feces compared to healthy individuals. The study suggests a possible link between microplastic exposure and IBD, but the exact relationship remains unclear.